At Close: Dec 08, 2023
3 Biotech Stocks That Are Poised to Have Breakthroughs in 202408:18am, Sunday, 12'th Nov 2023
When it comes to biotech stocks, I usually like to take a “Goldilocks” approach. This involves investing in biotech companies that have one or more promising drugs in mid-to-late stage clinical tr
7 Underappreciated Biotech Stocks to Pick Up on the Cheap10:01pm, Thursday, 09'th Nov 2023
Amid some rising questions for the economy, value-seeking investors may want to consider underappreciated biotech stocks. As a sector that, while not immune to broader pressures, generally manages to
Incyte (INCY) Beats on Q3 Earnings, Misses Revenue Estimates01:31pm, Tuesday, 31'st Oct 2023
Incyte's (INCY) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens Jakafi net product revenue guidance for 2023.
Incyte Corporation (INCY) Q3 2023 Earnings Call Transcript12:23pm, Tuesday, 31'st Oct 2023
Incyte Corporation (NASDAQ:INCY ) Q3 2023 Earnings Call Transcript October 31, 2023 8:00 AM ET Company Participants Ben Strain - Head of Investor Relations Herve Hoppenot - President and Chief Executi
Drugmaker Incyte's quarterly profit beats on lower costs09:48am, Tuesday, 31'st Oct 2023
Incyte reported a third-quarter profit on Tuesday that beat analysts' estimates as lower costs helped offset weak sales of its blood cancer drug Jakafi.
Incyte (INCY) Stock Plummets 29.6% Year to Date: Here's Why02:16pm, Friday, 13'th Oct 2023
Incyte (INCY) loses 29.6% year-to-date as competition increases for Jakafi and the company suffers pipeline setbacks.
Incyte (INCY) Posts Upbeat Data From Phase II Vitiligo Study12:47pm, Thursday, 12'th Oct 2023
Incyte (INCY) announces new positive 52-week data from its mid-stage study of povorcitinib for the treatment of adult patients with extensive nonsegmental vitiligo.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress.
3 Biotech Stocks That Should Be on Every Investor's Radar This Fall02:15pm, Wednesday, 20'th Sep 2023
The Federal Reserve's decision on interest rates will impact the short-term outlook of the economy. However, even with higher-for-longer interest rates, drug discovery moves on.
Incyte (INCY) Down on FDA Nod for Another Myelofibrosis Drug09:46am, Tuesday, 19'th Sep 2023
Incyte (INCY) declines on potential competition for lead drug Jakafi from Ojjaara for the treatment of intermediate or high-risk myelofibrosis.
Incyte shares drop after FDA approves GSK's competing blood-cancer treatment08:11am, Monday, 18'th Sep 2023
Incyte Corp. INCY, -1.47% shares dropped more than 5% premarket on Monday after the U.S. Food and Drug Administration on Friday approved a GSK PLC GSK, +0.11% blood-cancer treatment, Ojjaara, that wil
Compared to Estimates, Incyte (INCY) Q2 Earnings: A Look at Key Metrics11:10am, Tuesday, 01'st Aug 2023
Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street es
Incyte beats estimates on high demand for cancer drug Jakafi08:24am, Tuesday, 01'st Aug 2023
Incyte Corp on Tuesday reported second-quarter profit and revenue above Wall Street estimates as demand for its blood cancer drug Jakafi and skin disorder drug Opzelura picked momentum.
Incyte's (INCY) Opzelura Meets Goal in Phase III Pediatric Study12:34pm, Wednesday, 12'th Jul 2023
Incyte's (INCY) Opzelura (ruxolitinib cream) meets the primary endpoint in a phase III study in children with atopic dermatitis.